FDC Limited Posts Robust Q1 FY26 Results with Strong Revenue and Profit Growth

FDC Limited, a major name in India’s pharmaceutical industry, has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The results were declared following the board meeting held on August 7, 2025, as per the company’s filing to BSE and NSE under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Board Meeting Overview and Disclosure Compliance

The Board of Directors of FDC Limited reviewed and approved the quarterly financial results along with a limited review report by statutory auditors BSR & Co. LLP. The board meeting began at 12:30 p.m. and concluded at 01:55 p.m.

As required by Regulation 30 and 33 of the SEBI Listing Regulations, the company submitted both standalone and consolidated financial statements, ensuring full compliance with regulatory norms.

Standalone Financial Performance – Q1 FY26

FDC’s standalone performance shows a net profit of ₹12,219.08 lakh for Q1 FY26, compared to ₹11,496.89 lakh in Q1 FY25. This indicates a year-on-year (YoY) growth of approximately 6.3%. The company posted total income of ₹67,786.66 lakh, up from ₹65,220.42 lakh YoY.

Key Highlights – Standalone (₹ in lakh):

• Revenue from operations: ₹64,228.11

• Other income: ₹3,558.55

• Total income: ₹67,786.66

• Total expenses: ₹51,698.21

• Profit before tax: ₹16,088.45

• Net profit: ₹12,219.08

• EPS (Basic and Diluted): ₹7.51

The growth in profit is attributed to higher revenue, effective cost management, and stable operating margins. The company also recorded lower finance costs, ensuring a healthy bottom line.

Consolidated Financial Performance – Q1 FY26

On a consolidated basis, which includes contributions from subsidiaries in the United Kingdom, United States, and South Africa, FDC reported a net profit of ₹12,335.14 lakh for the quarter, showing a 3.6% YoY increase compared to ₹11,903.50 lakh in Q1 FY25.

Key Highlights – Consolidated (₹ in lakh):

• Revenue from operations: ₹64,840.58

• Other income: ₹3,550.42

• Total income: ₹68,391.00

• Total expenses: ₹52,413.47

• Profit before tax: ₹15,977.53

• Net profit: ₹12,335.14

• EPS (Basic and Diluted): ₹7.45

The subsidiaries’ performance, especially from FDC International (UK), FDC Inc. (USA), and Fair Deal Corporation Pharmaceuticals SA (South Africa), added positively to the consolidated numbers. Their operations are contributing meaningfully to group revenue and profit growth.

Other Key Disclosures

Tax Expense and Deferred Tax:
FDC paid ₹3,500 lakh in current tax and reported a deferred tax impact of ₹369.37 lakh for the standalone results. Consolidated tax stood at ₹3,842.39 lakh.

Employee Benefits and Material Costs:
Employee expenses for the quarter stood at ₹13,113.58 lakh (standalone), indicating the company’s commitment to human capital. Material consumption costs were ₹17,566.12 lakh, in line with operational volume.

Depreciation and Other Expenses:
Depreciation and amortisation were ₹1,487.46 lakh for the standalone business and ₹1,490.68 lakh on a consolidated basis. Other expenses saw a modest increase, reaching ₹16,645.42 lakh (consolidated).

Limited Review Reports – Standalone and Consolidated

The statutory auditors conducted a limited review for both standalone and consolidated statements and provided an unmodified conclusion, confirming there were no material misstatements or audit qualifications.

In both reports, the auditors mentioned that:

“Nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement.”

Also, the review of overseas subsidiaries revealed no significant issues, and the results from these entities were not material enough to impact the group’s overall numbers.

Fair Value Adjustments and Dividend Disclosure

FDC recognised a fair value loss of ₹197.01 lakh under other expenses in Q4 FY25 but also reported a net fair value gain of ₹2,430.09 lakh for FY25 under other income. These adjustments, as per Ind AS 109, affect quarterly performance but balance out annually.

Earlier, in FY25, the company had also declared an interim dividend of ₹5/- per equity share, demonstrating consistent shareholder returns.

Segment Reporting and Activity

The company continues to operate in a single segment – Pharmaceuticals, making it a focused player in the pharma space. This allows for targeted investments, operational efficiencies, and sector-specific expertise.

Digital Access to Results

The complete set of unaudited results and audit review reports are accessible on:

• FDC website: www.fdcindia.com

• NSE: www.nseindia.com

• BSE: www.bseindia.com

Conclusion

FDC Limited has delivered a strong Q1 FY26 performance, with robust revenue growth, stable profit margins, and clean audit reviews. The company continues to show resilience in a competitive pharmaceutical landscape with healthy contributions from both domestic and international operations.

Its clear focus on pharma sector innovation, sustainable business practices, and stakeholder returns positions FDC as a key player to watch in the coming quarters.

Investors and stakeholders can look forward to a sustained upward trajectory as the company leverages its global presence and strong fundamentals in the pharmaceutical sector.

The Upcoming IPOs in this week and coming weeks are Regaal Resources, Mahendra Realtors and Infrastructure, Bluestone Jewellery and Lifestyle, Icodex Publishing Solutions, Star Imaging and Path Lab, Medistep Healthcare, ANB Metal Cast.

The Current active IPO are ConnPlex Cinemas, ALL Time Plastics, JSW Cement, Sawaliya Foods Products, Highway Infrastructure.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.